The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic…

Melanoma Stage IIIMelanoma Stage IVBRAF V600 Mutation

~Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT04741997

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

~Estimated

~$10 – $7,500

Phase 2

A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 …

BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more

~Estimated

~$10 – $5,625

University of California, San FranciscoNCT07110246

Institut de Recherches Internationales Servier

NCT05786924